There is more to Medicare coverage for Alzheimer’s treatment than Leqembi, Eisai Co., Ltd. and Biogen, Inc.’s newly-approved amyloid-targeting monoclonal antibody. Now the program also is considering amending restrictive coverage policies for PET scans and genetic testing that help target the drug to the right patients.
Key Takeaways
-
Medicare will resume efforts to revise its restrictive national coverage policy for beta amyloid-PET scans in the near future.
Leqembi was approved 6 July by the US Food and Drug Administration, making it the first amyloid beta-directed antibody –...







